Skip to Content

David Marin, MD, DM, MSc

Present Title & Affiliation

Primary Appointment

Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit 0423
Houston, TX 77030
Phone: (713) 792-7179
Fax: (713) 794-4902

Education & Training

Degree-Granting Education

2007 University of London, London, United Kingdom, DM, Doctor of Medicine (equivalent to PhD)
2000 Universidad Autonoma de Barcelona, Barcelona, Spain, MSc, Graduate in Statistical Methods in Health Sciences (equivalent to MSc)
1994 Universidad Autonoma de Barcelona, Barcelona, Spain, MD, Titulo de Licenciadeo de Medicina Cirugia (equivalent to MD)

Board Certifications

1998 Boards in Hematology (Spain)

Experience/Service

Academic Appointments

Reader in onco-haematology, Hammersmith Hospital, Imperial College, London, United Kingdom, 9/2009-5/2014
Senior Lecturer, Hammersmith Hospital, Imperial College, London, United Kingdom, 6/2004-9/2009

Honors and Awards

2010 Fellowship of the Royal College of Physicians (FRCP), Royal College of Physicians, London, England

Selected Publications

Peer-Reviewed Original Research Articles

1. Marin D. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next? J Clin Oncol 32(5):379-84, 2/2014. e-Pub 1/2014. PMID: 24419129.
2. Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121(14):2739-42, 4/2013. e-Pub 2/2013. PMID: 23380743.
3. Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, Pocock C, Goldman JM, O'Brien S. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120(2):291-4, 7/2012. e-Pub 5/2012. PMID: 22645182.
4. Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 26(2):296-302, 2/2012. e-Pub 8/2011. PMID: 21844874.
5. Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, Reid A, Rezvani K, Foroni L, Goldman J, Marin D. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 119(8):1838-43, 2/2012. e-Pub 12/2011. PMID: 22174159.
6. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232-8, 1/2012. e-Pub 11/2011. PMID: 22067393.
7. Goldman JM, Gordon M, Bazeos A, Marin D. Biology of CML stem cells: the basis for clinical heterogeneity? Leukemia(1):S43-S45, 2012.
8. Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012:115-21, 2012. PMID: 23233569.
9. Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo R, Goldman J, Marin D. Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica 96(12):1779-82, 12/2011. e-Pub 8/2011. PMCID: PMC3232259.
10. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733-6, 4/2011. e-Pub 2/2011. PMID: 21346253.
11. Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, Foroni L, Reid A, de Lavallade H, Rezvani K, Dazzi F, Apperley JF, Goldman JM, Marin D. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 116(25):5497-500, 12/2010. e-Pub 9/2010. PMID: 20833982.
12. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381-8, 5/2010. e-Pub 4/2010. PMID: 20385986.
13. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM, Marin D. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95(2):224-31, 2/2010. e-Pub 10/2009. PMCID: PMC2817024.
14. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JF. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112(12):4437-44, 12/2008. e-Pub 8/2008. PMID: 18716134.
15. Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26(29):4806-13, 10/2008. e-Pub 7/2008. PMID: 18645191.
16. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26(20):3358-63, 7/2008. e-Pub 6/2008. PMID: 18519952.
17. de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM, Apperley JF, Marin D. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 110(7):2779-80, 10/2007. PMID: 17881650.
18. Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 103(9):1850-5, 5/2005. PMID: 15786422.
19. Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, Andreasson C, Bua M, Olavarria E, Rahemtulla A, Dazzi F, Kanfer E, Goldman JM, Apperley JF. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 19(4):507-12, 4/2005. PMID: 15703781.
20. Marin D, Rahemtulla A, Olavarria E, Goldman J, Apperley J. Interactive web-based guidelines for chronic myeloid leukaemia. Lancet 363(9416):1239, 4/2004. PMID: 15081671.
21. Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I, Foot N, Crawley C, Na Nakorn T, Olavarria E, Lennard A, Neylon A, O'Brien SG, Goldman JM, Apperley JF. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 17(8):1448-53, 8/2003. PMID: 12886230.
22. Marin D, Marktel S, Szydlo R, Klein JP, Bua M, Foot N, Olavarria E, Shepherd P, Kanfer E, Goldman JM, Apperley JF. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet 362(9384):617-9, 8/2003. PMID: 12944062.
23. Goldman J, Apperley J, Kanfer E, Olavarria E, Marin D. Imatinib or transplant for chronic myeloid leukaemia? Lancet 362(9378):172-3, 7/2003. PMID: 12867128.
24. Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, De Melo VA, Kotzampaltiris P, Dazzi F, Rahemtulla A, Olavarria E, Apperley JF, Goldman JM. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 88(3):260-7, 3/2003. PMID: 12651263.

Last updated: 12/10/2014